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Abstract 
The traditional family-history approach to genetic testing involves taking a detailed three 
generation family-history from both sides of the family, ethnicity, type of cancer, age of 
onset and death. Testing for BRCA1/BRCA2 mutations is offered at a ≥10% combined 
BRCA1/BRCA2 probability. Risk models such as the Manchester scoring system, BOADICEA, 
BRCAPRO can be used to calculate BRCA1/BRCA2 probability. High-risk women identified 
should be referred to a regional genetics service for genetic counselling and testing. The 
Amsterdam-Criteria-2 have been traditionally used to identify Lynch Syndrome (caused by a 
mismatch repair gene (MLH1/MSH2/MSH6/PMS2) mutation). Molecular 
(immunohistochemistry and Microsatellite instability) analysis of tumour tissue is now 
established as an initial step, with genetic testing undertaken for protein deficient or MSI 
unstable tumours. This is offered for those fulfilling Bethesda criteria and recently for all 
colorectal cancer cases <60 years. BRCA1/BRCA2 testing is recommended for all non-
mucinous invasive epithelial ovarian cancers irrespective of family-history (10-20% have a 
BRCA1/BRCA2 mutation). This is being undertaken by non-genetics clinicians. A population-
based approach to genetic testing identifies 50% more carriers at risk.  It has been 
extensively investigated in the Ashkenazi-Jewish population and found to be extremely cost-
effective in this community. This is expected to lead to change in guidelines in the future. 
 
Keywords 
BRCA, genetic testing, risk prediction, ovarian cancer, breast cancer, endometrial cancer, 
Lynch Syndrome, high risk 
  
Genetic Testing for Gynaecological Cancer 
 
Introduction 
The traditional approach to genetic testing for high penetrance gynaecological cancer gene 
mutations has been driven by family history (FH). This involves testing affected individuals 
from high-risk families through specialist cancer genetics clinics following intensive face-to-
face genetic counselling. It requires both the individual patient as well as the clinical 
practitioner to be aware of the FH, appreciate the risk/significance of the FH and to act on it.  
The usually encountered hereditary gynaecological cancer syndromes include hereditary 
breast and/or ovarian cancer syndrome, Lynch Syndrome (or Hereditary Non-Polyposis 
Colorectal Cancer – HNPCC), Cowden’s Syndrome and Peutz–Jeghers syndrome.  
 
Hereditary breast and/or ovarian cancer 
Autosomal dominant mutations in the BRCA1/BRCA2 genes account for most of the known 
hereditary risk of ovarian cancer. Women carrying BRCA1/BRCA2 genes have an 18-40% risk 
of ovarian cancer and 45-65% risk of breast cancer (higher risk estimates are obtained from 
data analysed from cancer genetics clinics which are uncorrected for ascertainment). 
Additionally, newer moderate penetrance genes (ovarian cancer risks 5%-9%) like the 
RAD51C, RAD51D and BRIP1 have been recently identified and validated risk estimates 
published. In the general population- around 1:300 – 1:400 individuals carry a BRCA1/BRCA2 
mutation. In certain populations called founder populations (such as Ashkenazi Jews), 
BRCA1/BRCA2 mutations occur more frequently. 1:40 Ashkenazi Jewish individuals carry one 
of the three common BRCA1/BRCA2 mutations called founder mutations.  
 
Over the years, a number of risk assessment models have been developed and modified. 
Models vary widely with respect to the data used to derive them, the study design, level of 
detail of FH, risk factors and the specifics of genetic transmission patterns included. Hence, 
each model has strengths and weaknesses dependent upon population characteristics, 
methodology, underlying assumptions and the statistical tools used to create them. Models 
are generally two types: Empiricial and Mendelian. Descriptive FH variables are used to 
develop Empirical models, typically using logistic regression.  These models are more 
straightforward to implement/use and can readily incorporate other non-genetic risk 
factors. A widely used example is the Manchester Scoring System (MSS). A major drawback 
is that they cannot adequately deal with complex family histories and MSS cannot be used 
for Ashkenazi Jewish families.  
 
Mendelian models use pedigree analysis and Mendelian rules of genetic inheritance to 
develop a genetic model for disease, usually based on Bayesian and other likelihood ratio 
analyses. They are able to account for complex family histories and provide individualised 
probabilities of carrying a mutation. BOADICEA (Cambridge, UK) and BRCAPRO (Bayes-
Mendel, USA) are commonly used examples. The National Institute of Health and Care 
Excellence (NICE) recommend that BRCA1/BRCA2 testing be offered to those who have a 
10% combined BRCA1/BRCA2 probability. This threshold of offering genetic testing in the UK 
was earlier 20% and was lowered to 10% in 2013.  
 
Models commonly used in the UK to estimate BRCA1/BRCA2 probability are – MSS, 
BOADICEA, Tyrer Cuzick (UK), BRCAPRO. MSS is an easy to use table which provides scores 
for BRCA1 and BRCA2 mutations based on female/male breast cancers, ovarian cancers, 
prostate and pancreatic cancers on the same side of the family. With the MSS, a combined 
score of 16 corresponds to the 10% testing threshold and a score of 20 to the 20% 
threshold. Table-1 provides easy to read risk criteria which have been adapted from criteria 
widely used to identify high risk women in the UKFOCSS national ovarian cancer screening 
trial and the London Cancer familial gynaecological cancer MDT (Barts Hosptial, UCLH). 
Different FH testing criteria exist for Jewish and the non-Jewish general population given the 
significantly different BRCA1/BRCA2 prevalence estimates (criteria being more lax in the 
latter). Thus taking a detailed FH is critical to risk assessment for considering genetic testing. 
This should include history from both maternal and paternal sides of the family, spanning at 
least 3 generations (first and second degree relatives), ethnicity, age of onset of cancer, type 
of cancer and age of death. Both affected and unaffected relatives should be noted. High-
risk women identified should be referred to a regional genetics service for genetic 
counselling and testing. 
 
Lynch Syndrome (LS) 
LS is an autosomal dominant syndrome, the tumour spectrum of which comprises colorectal 
(60% risk), endometrial (40-60% risk) and ovarian (approximate 10% (4-20%) risk) cancers. 
Additionally it also includes gastric, small bowel, hepato-biliary, brain, ureteric and renal 
pelvic (upper urologic tract) cancers. It is caused by a mutation in one of the mismatch 
repair (MMR) genes: MLH1, MSH2, MSH6 and PMS2. The Amsterdam criteria-2 (AC-2) have 
been traditionally used to identify LS. AC-2 includes at least 3 relatives in the family with one 
of the LS cancers, all of whom should be related by a first degree relationship, the LS cancers 
should span at least 2 generations and one should be <50 years. The AC-2 criteria miss a 
number of mutation carriers. Hence more lax criteria called Revised Bethesda criteria have 
been used to improve ascertainment by identifying colorectal cancer cases for molecular 
analysis (immunohistochemistry (IHC) and Microsatellite instability (MSI)) as an initial step, 
with genetic testing undertaken for IHC protein deficient or MSI unstable tumours. IHC/MSI 
testing for all colorectal cancer cases <60 years is now recommended as an unselected 
approach increases carrier deification and is cost-effective. IHC & MSI analysis for ‘all’ EC 
cases is more effective at identifying MMR carriers/LS than Bethesda/AC-2 criteria alone, 
which miss 12-30%/ 55-70% of carriers respectively. Although IHC and MSI testing for 
endometrial cancer cases have been recommended by some guidelines to better ascertain 
individuals for genetic testing for MMR mutations, this is not yet common practice in the 
UK. However, this is likely to change going forward. Such an approach of unselected testing 
if implemented for epithelial ovarian cancers would also be able to identify 1-2% additional 
LS carriers. However, this is not yet part of routine practice and the cost-effectiveness of this 
approach has not been evaluated.  
 
Systematic Epithelial Ovarian Cancer Case Series BRCA1/BRCA2 Testing 
Around 10%-20% of non-mucinous epithelial ovarian cancers have mutations in the 
BRCA1/BRCA2 genes. Around half of these would not be identified by the traditional FH 
based testing. NHS England and NICE guidelines now recommend BRCA1/BRCA2 testing for 
all women with non-mucinous high grade invasive epithelial ovarian cancer. This is gradually 
being implemented across the UK. In addition to predictive testing of unaffected family 
members, an added advantage is access to PARP inhibitors for those who develop Platinum 
sensitive relapsed ovarian cancer. Different models of pre-test counselling have been 
followed for this: (a) traditional approach of face-to-face counselling by the genetics 
clinician/genetic counsellor in a specialist genetics clinic; (b) telephone counselling by the 
genetics clinician/genetic counsellor in a specialist genetics clinic; (c) Mainstreaming – non 
genetics clinician performing pre-test counselling after online training and post-test 
counselling undertaken by the regional genetics service; (d) GTEOC Cambridge model: 
genetics co-ordinated testing through local non-genetics clinicians. 
 
 RAD51C, RAD51D and BRIP1 mutations: 
Genetic testing for these ovarian cancer gene mutations is not yet routine practice. 
However, a recent paper showed it would be cost-effective to offer risk reducing surgery at 
the levels of risk associated with these gene mutations. This provides clinical utility for 
genetic testing at these levels of risk, and suggests guidelines need changing in this respect.  
 
Cowden’s Syndrome  
Autosomal dominant condition caused by PTEN gene mutations. It is associated with a 10-
28% risk of endometrial cancer, 50% risk of breast cancer and 3-10% risk of thyroid cancer. 
 
Peutz-Jeghers Syndrome- 
This is caused by a mutation in the STK11/LKB1 gene. The condition is associated with an 
increased risk of cervical cancer (adenoma malignum), sex cord stromal ovarian tumours 
and breast cancer. 
 
Population based testing- 
FH based prediction models are only moderately effective at predicting the presence of a 
BRCA1/BRCA2 mutation and have a poor ability for predicting their absence. A large 
proportion (approximately 50%) of mutation carriers do not give a strong FH of cancer and 
will not be detected by current clinical means. Given the significant benefits of screening/ 
prevention available to mutation carriers, this questions the efficacy of the current FH based 
approach. These limitations can be overcome using a population-based approach to genetic 
testing. 
 A population testing approach for BRCA1/BRCA2 mutations has been extensively 
investigated in the Ashkenazi Jewish population and shown to identify 50% more people at 
risk, not detrimentally affect psychological health and can be highly cost-effective for the 
NHS, saving both lives and money. While there is strong evidence to suggest need for 
changing the clinical paradigm in this population to population based BRCA1/BRCA2 testing, 









 Table-1. Criteria to identify high risk families (London Cancer MDT) 
Volunteer/Proband should either have been affected by cancer or be a FDR of an affected 
family member 
Families with ovarian* or ovarian* and breast cancer 
1) >2 individuals with ovarian cancer (any age) who are first degree relatives (FDR). 
2) 1 ovarian cancer (any age) and 1 breast cancer <50 who are FDR. 
3) 1 ovarian cancer (any age) and 2 breast cancers <60 who are FDR. 
4) Breast cancer in volunteer/proband (<45 years) and mother with both breast and ovarian 
cancer (in the same person). 
5) Breast cancer in volunteer/proband (<40 years) and sister with both breast and ovarian 
cancer (in the same person). 
6) Criteria 1, 2 and 3 can be modified where paternal transmission is ocuring i.e. families 
where affected relatives are related by second through an unaffected intervening male relative 
and there is an affected sister eligible. 
* History of tubal/primary peritoneal cancers may be considered equivalent to ovarian cancer. 
Families with a known gene mutation 
7) The family contains an affected individual with a mutation in 1 of the known ovarian / 
endometrial cancer predisposing genes e.g. BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, PTEN, 
STK11/LKB1 
Lynch Syndrome / HNPCC Families 
8) The family contains 3 or more individuals with a LS or HNPCC related cancer*, who are FDR 
and >1 case is diagnosed before 50 years and the cancers affect >1 generation. 
*LS or HNPCC related cancers include: colorectal, endometrial, small bowel, ureteric and renal 
pelvic cancers. 
Families with only breast cancer 
9) ≥4 breast cancers in the family (any ages) 
10) 3 breast cancers related by FDR:  
i) 1 <3O years or 
ii) All <4O years or 
iii) 1 male breast cancer (MBC) and 1 bilateral breast cancer. 
11) Breast cancer in volunteer/proband (<50 years) and: 
i) Breast cancer in mother (age of onset being <30 in one and <50 years in the other) or 
ii) Bilateral breast cancer in mother (<40 years onset) or 
iii) 1 MBC and 1 bilateral breast cancer. 
12) 2 MBC (1 <40 years) in the family and proband is a FDR of 1 of them. 
Families with Ashkenai Jewish (AJ) ancestory  
13) Breast cancer (<40 years) or bilateral breast cancer (first cancer <50 years) in 
volunteer/proband irrespective of family history of cancer. 
14) Breast cancer in volunteer/proband (<50 years) and 1 FDR with breast cancer (<50 years) 
or ovarian cancer (any age) or MBC (any age). 
15) Breast cancer in volunteer/proband (<60 years) and 1 FDR with breast cancer (<40 years) 
or ovarian cancer (any age) or MBC (any age). 
16) 1 FDR with ovarian cancer (<50 years). 
17) FDR with breast and ovarian cancer in the same woman (any age). 
18) 2 FDR with breast cancer (<40 years). 
19) 2 MBC (<60 years) in the family and proband is a FDR of 1 of them. 
20) Breast Cancer in self <50 years or Ovarian cancer in self at any age 
Women with non-mucinous invasive epithelial ovarian cancer (EOC) 
21) Women with invasive non mucinous EOC regardless of family history/ethnicity. 
Women with triple negative (TN) Breast Cancer <50 years 
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